CAS: 105331-00-8; 4,6-Diamino-1-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(Hydroxymethyl)Tetrahydrofuran-2-yl)-1,3,5-Triazin-2(1H)-One
该化合物是一种核分子类比,在遗传学研究和肿瘤学中具有显著应用.作为5-azacytidine的衍生物,它作为DNA甲基转移酶抑制剂发挥作用,有效诱发低甲基化和重新激活静态基因.它的结构性改变与其母体化合物相比,增强了稳定性和生物利用率,使其成为研究DNA甲基化动态的宝贵工具.这一化合物在调查血液恶性肿瘤和固态肿瘤方面特别有用,因为异常甲基化在其中发挥着关键作用.它调节高特殊性基因表达的能力凸显了它在机械学研究和潜在治疗发展两方面的效用.
- 英文名称4,6-Diamino-1-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(Hydroxymethyl)Tetrahydrofuran-2-yl)-1,3,5-Triazin-2(1H)-One
- 中文名称6-氨基-5-氮杂胞苷
- IUPAC名称4,6-diamino-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one
- 其它别名6-Amino-5-Azacytidine; 4,6-Diamino-1-Beta-D-Ribofuranosyl-1,3,5-Triazin-2(1H)-One; 4,6-Diamino-1-(β-D-Ribofuranosyl)-1,3,5-Triazin-2(1H)-One; 4,6-Diamino-1-((2R,3R,4S,5R)-3,4-Dihydroxy-5-(Hydroxymethyl)Tetrahydrofuran-2-yl)-1,3,5-Triazin-2(1H)-One; 4,6-Diamino-1-((2R,3R,4S,5R); 1,3,5-Triazin-2(1H)-One, 4,6-Diamino-1-β-D-Ribofuranosyl-; Azacitidine Impurity Abcdefg; 6-Amino-5-Azacytidine Formate Salt
- CAS编号105331-00-8
- MFCD编号:MFCD30186651
- FDA UNII编号:QS4CCV9ZS5
- 分子式:C8H13N5O5分子量:259.22
- 产品CID: 94240
- 产品分类分析化学 → 标准品 → 药典标准品和杂质标准品
物理性质
上下游产品
6-methoxy-5-azacytidine 2',3',5'-tri-O-benzoyl-6-ethoxy-5-azacytidine合成工艺路线路线简述
📜2',3',5'-Tri-O-Benzoyl-6-Ethoxy-5-Azacytidine置于氨体系中,用 甲醇 用作溶剂,以81%的收率获得6-氨基-5-氮杂胞苷
参考文献:Piskala,Alois; Hanna,Naeem B.; Zajicek,Jaroslav,Collection Of Czechoslovak Chemical Communications,1989,Vol. 54,# 9,P. 2502-2511
标题:Piskala,Alois; Hanna,Naeem B.; Zajicek,Jaroslav,Collection Of Czechoslovak Chemical Communications,1989,Vol. 54,# 9,P. 2502-2511
海关参考信息
- 2905122000-异丙醇
2905310000-1,2-乙二醇
2905320000-1,2-丙二醇
2905399001-1,3-丙二醇
2905399002-1,4-丁二醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-9951098-B2
优先权日:2011-03-31
标题 :Synthesis of 5-azacytidine
发明人：RAJENDIRAN CHINNAPILLAI; NAGARAJAN PERIYANDI; VENKATESWARLAU JASTI
权利人:RAJENDIRAN CHINNAPILLAI; NAGARAJAN PERIYANDI; VENKATESWARLAU JASTI; PHARMION LLC
摘要:Provided herein are processes for the preparation of 5-azacytidine, useful for treating, preventing, and/or managing diseases or conditions including cancer, disorders related to abnormal cell proliferation, hematologic disorders, and myelodysplastic syndromes (MDS), wherein 5-azacytidine is represented by the structure:
专利号:US-2014128593-A1
优先权日:2011-03-31
标 题 :Synthesis of 5-azacytidine
专利号:EP-2691408-B1
优先权日:2011-03-31
标 题 :Synthesis of 5-azacytidine
专利号:KR-20140019820-A
优先权日:2011-03-31
标题:Synthesis of 5-azacytidine
专利号:CN-103619864-A
优先权日:2011-03-31
标 题:Synthesis of 5-azacytidine
